Jun 12, 2023, 03:13
The third country worldwide to approve this medication for HCC in combination with Durvalumab – Prof.Humaid Al-Shamsi
Last night in Dubai , in collaboration with AstraZeneca we successfully launched tremelimumab for the treatment of hepatocellular carcinoma (HCC). This remarkable achievement makes us the third country worldwide to approve this medication for HCC in combination with Durvalumab. Our unwavering commitment to providing the most advanced treatments for our patients in the UAE and the region remains steadfast.
Source: Prof.Humaid Al-Shamsi/Linkedin
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43